These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 17606315

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
    Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ.
    Br J Cancer; 2008 Jul 22; 99(2):230-8. PubMed ID: 18612311
    [Abstract] [Full Text] [Related]

  • 6. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ.
    Vaccine; 2008 Jul 29; 26(32):4015-24. PubMed ID: 18602731
    [Abstract] [Full Text] [Related]

  • 7. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.
    Vaccine; 2013 Dec 30; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [Abstract] [Full Text] [Related]

  • 8. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ, O'Shea M, Diaz M, Kim SY.
    Reprod Health Matters; 2008 Nov 30; 16(32):86-96. PubMed ID: 19027626
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 10. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M.
    Cancer; 2007 Jun 25; 111(3):145-53. PubMed ID: 17487850
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ.
    Vaccine; 2013 Dec 31; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [Abstract] [Full Text] [Related]

  • 12. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A, Schwarz TF, Hammerschmidt T, Siebert U.
    Med Klin (Munich); 2007 Jul 15; 102(7):515-23. PubMed ID: 17634869
    [Abstract] [Full Text] [Related]

  • 13. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C.
    Vaccine; 2009 Oct 09; 27(43):6060-79. PubMed ID: 19647813
    [Abstract] [Full Text] [Related]

  • 14. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA, Daemen T, Postma MJ, Wilschut JC.
    Ned Tijdschr Geneeskd; 2009 Oct 09; 153():A356. PubMed ID: 19930733
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.
    Arch Med Res; 2009 Aug 09; 40(6):503-13. PubMed ID: 19853192
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.
    Int J Technol Assess Health Care; 2008 Aug 09; 24(1):10-9. PubMed ID: 18218164
    [Abstract] [Full Text] [Related]

  • 17. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
    Gauthier A, Martín-Escudero V, Moore L, Ferko N, de Sanjosé S, Pérez-Escolano I, Catalá-López F, Ferrer E, Bosch FX.
    Eur J Public Health; 2008 Dec 09; 18(6):674-80. PubMed ID: 18641420
    [Abstract] [Full Text] [Related]

  • 18. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 19. Mathematical models of cervical cancer prevention in Latin America and the Caribbean.
    Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY.
    Vaccine; 2008 Aug 19; 26 Suppl 11():L59-72. PubMed ID: 18945403
    [Abstract] [Full Text] [Related]

  • 20. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J.
    Vaccine; 2007 Sep 17; 25(37-38):6677-91. PubMed ID: 17706844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.